H2U, Taiwan’s leading digital health brand, announced that it has raised over 10 million USD in its Series B round of funding before the lunar new year.

The round was led by Korea’s largest medical laboratory, Seoul Clinical Laboratories (SCL), and joined by Taiwan’s biggest food company, Standard Foods, the leading protein and antibody reagent innovator and manufacturer, Leadgene Biomedical, and AWS cloud services representative, GrandTech C.G. Systems.

These strategic partners will provide H2U with strong support in research and development, AI data insights, and product promotion.

H2U, which stands for Health to You, has been established for ten years and has over 3 million platform members. The company offers a digital health ecosystem platform called H2U pano, which provides holistic healthy life solutions for thousands of domestic companies.

H2U pano covers digital health management, personalized medical checkup plan, precise nutritional science, individualized sports prescriptions, and corporate health promotion. H2U pano also guides members through a holistic digital health journey, from booking medical appointments to collecting post-examination reports.

With user permission, H2U’s AI engine can conduct a health risk assessment and recommend suitable personalized health plans, high-quality health products, diverse health-related courses, exercise prescriptions, and Lohas services.

H2U’s vision is to improve the health of Taiwanese people and expand its presence in the international market. The company plans to enter the Korean medical market via the SCL Group in the first half of 2024 by building a SaaS-based digital health check platform and a closed-loop post-check health management program within South Korean medical examination centers.

H2U will also leverage SCL’s extensive business territory in Northeast and Southeast Asia to develop the overseas market. In addition, H2U plans to attend annual international medical events like Medica Germany, CES, and the J.P. Morgan Healthcare Conference USA. The company’s aspiration is to become Asia’s renowned digital health unicorn and undergo an IPO by the end of this year.